Why the study?
Does long-term antidepressant therapy reduce relapse and recurrence in patients with depression?
Does long-term antidepressant therapy reduce relapse and recurrence in patients with depression?
Long-term antidepressant therapy significantly reduces the risk of relapse and recurrence in patients with depression.
May support maintenance antidepressants in recurrent depression; leaves open optimal duration and patient selection for prospective trials.
BACKGROUND: Depression, which only a few decades ago was considered to be a short-term illness requiring short-term treatment, is now recognised as a recurrent, sometimes chronic, long-term illness. AIMS: To highlight the clinical importance of long-term antidepressant therapy in the treatment of depression. METHOD: The current literature was reviewed to examine the relationship between duration of antidepressant therapy and efficacy. RESULTS: Approximately one-third to a half of patients successfully stabilised in acute-phase treatment will relapse if medication is not sustained throughout the continuation period. Only 10-15% will relapse if medication is continued. For maintenance-phase therapy, approximately 60% of patients at risk will experience a recurrent episode of depression within 1 year if untreated, whereas those who continue in treatment will have a recurrence rate of between 10% and 30%. CONCLUSIONS: Risk of relapse and recurrence of depression can be significantly reduced if adequate continuation and maintenance therapy durations are achieved.
No takes yet. Share an insight, caveat, or question.
Robert M. A. Hirschfeld (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: